Healthcare stocks are mostly lower, with the NYSE Healthcare
Sector Index retreating about 0.5% and shares of healthcare
companies in the S&P 500 declining 0.3% as a group.
In company news, ImmunoGen Inc. (
) is down more than 20% at $13.15 a share after the drug-maker said
it was stopping Phase II testing of its IMGN901 prospective
treatment for small-cell lung cancer after trial results showed the
drug didn't improve survival rates.
The trial was halted at the recommendation of the Independent
Data Monitoring Committee, which also said all patients should
In other sector news,
(+) CYTX, (+70.6%) Inks deal with Lorem Vascular to
commercialize Cytori Cell Therapy for the cardiovascular, renal and
diabetes markets in China, Hong Kong, Malaysia, Singapore and
Australia. Lorem committed to pay up to $531 mln in licensing
(-) GTIV, (-13.1%) Q3 earnings of $0.15 per share, ex items,
trailing analyst projections by $0.07. Revenue fell 3.3% year over
year to $410.5 mln, mising the Capital IQ consensus by $4.56 mln.
Sees FY13 EPS in-line with estimates.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.